Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)
Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click to find out ...
Fierce Pharma7d
J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms
Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...
BioSpace6d
J&J, Legend Pump $150M Into Manufacturing in Bid to Double Carvykti Production
Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...
Investing2d
Legend Biotech’s SWOT analysis: carvykti’s strong efficacy drives stock outlook
Legend Biotech’s financial performance has been strong, with Carvykti sales showing significant growth. According to InvestingPro analysis, the company maintains a healthy financial position ...
Legend Biotech Corp (LEGN) Q4 2024 Earnings Call Highlights: Record CARVYKTI Sales and ...
Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales, outlines expansion strategies, and anticipates ...
Legend Biotech (LEGN) Blockbuster Fuels Expectation-beating Growth
Legend Biotech’s (LEGN) shares have surged over 10% in the past few days, spurred by the company’s latest earnings report, thanks to ...
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 ...
Nasdaq8d
Legend Biotech Reports $963 Million in CARVYKTI® Sales for 2024 and Initiates Commercial Production at Novartis Facility
We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as “ANI per Share”) as performance metrics. Adjusted Net Loss and ANI per Share are not defined under IFRS ...